UK’s Competition Body Says Pharma Firms Can Work Together On Access To Combination Therapies

The UK’s Competition and Markets Authority will not prioritize the investigation of pharmaceutical companies that enter commercial negotiations with the aim of making combination therapies cost effective, a move that the ABPI says is an “international first”.